Asthma Therapy 2026: Biologics, Nanoparticles & Digital Health

Abstract

🎯

Purpose of Review

Synthesise 2020–2025 evidence on emerging asthma treatment strategies
Focus on biologics across asthma subtypes, nanoparticle drug delivery, and digital adherence tools
Critically appraise clinical maturity and implementation challenges of each approach

🔬

Recent Findings

Biologics (anti-IgE, anti-IL-5, anti-IL-4/13, anti-TSLP) consistently reduce exacerbations and corticosteroid use in Th2-high asthma — clinically established and approved
Regenerative and gene therapies (MSC, siRNA/miRNA, mRNA vaccines) remain largely preclinical — mechanistically promising but not clinically ready
Nanoparticle delivery and digital health (smart inhalers, DTx, environmental sensors) show real-world promise but face cost, integration, and long-term evidence barriers

Asthma management is shifting toward precision, subtype-informed care. Biologics now offer highly effective options for severe Type 2 (allergic/eosinophilic) asthma, but patients with non-Type 2 disease remain underserved. Advanced delivery platforms and digital tools address adherence gaps. Future progress requires longer-term outcome data, better biomarkers for patient selection, and strategies to reduce cost barriers.

Introduction & Background

Asthma is a common, chronic inflammatory airway disease affecting people of all ages. It causes recurrent episodes of wheeze, breathlessness, chest tightness, and cough. Despite available treatments, asthma remains a major global health burden — affecting an estimated 300 million people worldwide — and accounts for substantial morbidity, healthcare costs, and preventable deaths.

Advances in molecular immunology have clarified why biologics work dramatically in Type 2 (Th2-high) asthma but remain inadequate for Th2-low (non-eosinophilic, neutrophilic) disease. This review examines how new therapeutic approaches — from precision biologics to nanoparticle carriers and AI-integrated digital tools — are reshaping asthma care across four domains.

While biologic therapies are now clinically established, other emerging approaches such as RNA-based therapeutics, stem cell–derived interventions, and nanoparticle platforms remain largely preclinical. Their translational potential and current evidence gaps are critically appraised in this narrative review.

Literature Search Strategy

This narrative review searched PubMed/MEDLINE, Cochrane Library, and EMBASE for original research articles, systematic reviews, meta-analyses, and clinical guidelines published between 2020 and 2025. Search terms included asthma, biologics, monoclonal antibodies, drug delivery, nanoparticles, smart inhalers, digital therapeutics, adherence, and disease management. Studies were included if they reported clinical, preclinical, or mechanistic evidence relevant to the three therapeutic domains covered.

Asthma Subtypes & Inflammation Pathways

Asthma is not a single disease. Two major inflammatory subtypes — Th2-high (eosinophilic/allergic) and Th2-low (neutrophilic/non-allergic) — have distinct immune mechanisms that determine which therapies will work. Understanding these subtypes is the foundation of precision medicine in asthma.

Th2-High Asthma (Allergic/Eosinophilic)

Triggered by allergen exposure activating airway epithelial alarmins (TSLP, IL-25, IL-33) and ILC2 cells.

Th2 cells release IL-4, IL-5, IL-9, IL-13 → eosinophil and mast cell activation
B cells produce IgE → bronchoconstriction, mucus production
Target for: Omalizumab (IgE), Mepolizumab/Benralizumab (IL-5), Dupilumab (IL-4/IL-13), Tezepelumab (TSLP)

Th2-Low Asthma (Neutrophilic/Non-Allergic)

Triggered by pollutants, infections, and smoking activating AECs to release IL-6 and IL-1β, driving ILC3 and Th17 responses.

IL-17 drives CXL8/G-CSF release → neutrophil recruitment and activation
Macrophage activation via IFN-γ → ROS/NOX4 → tissue damage and steroid resistance
Underserved by current biologics — no approved targeted therapy for neutrophilic asthma

Th2-high and Th2-low asthma immune pathways — **Figure 1.** Immunopathological mechanisms of Th2-high (allergic/eosinophilic, left) and Th2-low (neutrophilic/non-allergic, right) asthma. Th2-high inflammation is driven by allergen-induced alarmin release, ILC2 activation, and Th2-mediated eosinophilia and IgE production. Th2-low inflammation is driven by pollutants and infections activating ILC3, Th17, and macrophage-mediated ROS production. The pathway distinction explains the differential efficacy of current biologic therapies.

Key Immune Players by Asthma Subtype

Cell / Molecule	Endotype	Role in Asthma
B cells	Th2-high	Produce IgE antibodies under influence of IL-4
Antigen-presenting cells (APCs)	Both	Capture allergens; present to naïve T cells to initiate adaptive immune response
Eosinophils	Th2-high	Release MBP, ECP toxic granules; cause airway damage and chronic inflammation
Mast cells	Th2-high	Release histamine, leukotrienes, prostaglandins upon IgE activation → bronchoconstriction
Neutrophils	Th2-low	Release ROS and proteases; contribute to tissue damage and steroid resistance
ILC2	Th2-high	Amplifies Th2 inflammation from epithelial alarmins (TSLP, IL-25, IL-33)
ILC3	Th2-low	Secretes neutrophil chemoattractants; drives Th2-low inflammation
AECs (Airway epithelial cells)	Both	Detect allergens/pollutants; produce alarmins (TSLP, IL-33, IL-25, IL-6) to activate immune cells
Th2 cells	Th2-high	Drive eosinophilic inflammation via IL-4, IL-5, IL-9, IL-13
Th17 cells	Th2-low	Drive neutrophilic inflammation via IL-17
Macrophages (Th1-activated)	Th2-low	Activated by IFN-γ; produce ROS via NOX4 → epithelial damage and remodeling
IgE	Th2-high	Binds FcεRI receptors on mast cells/basophils; triggers pro-inflammatory mediator release
IL-4 / IL-13	Th2-high	Stimulate B cells to produce IgE; drive mucus production and airway hyperresponsiveness
IL-5	Th2-high	Promotes eosinophil growth, survival, and recruitment
TSLP	Both	Released by AECs; upstream activator of ILC2 and Th2 inflammation (key biologic target)
IL-17 (A, E, F)	Th2-low	Binds IL-17 receptor; stimulates CXL8/G-CSF release → neutrophil recruitment
CXL8 / G-CSF	Th2-low	Neutrophil chemoattractants produced in response to IL-17 signaling

Biologic Therapies

Biologics are the most clinically established class of emerging treatments for severe asthma. By targeting specific immune molecules, they offer precision therapy far more effective than broad corticosteroids for selected patient populations.

Biologics classification tree — **Figure 2.** Classification tree of approved asthma biologics. Six agents are now FDA-approved, targeting IgE (Omalizumab), IL-5/IL-5R (Mepolizumab, Reslizumab, Benralizumab), IL-4Rα (Dupilumab), and TSLP (Tezepelumab).

Omalizumab FDA Approved

Omalizumab is a monoclonal antibody targeting circulating IgE, preventing it from binding to high-affinity receptors (FcεRI) on mast cells and basophils. It is approved for moderate-to-severe allergic asthma and blocks the downstream cascade that triggers bronchoconstriction and inflammation.

Reduces asthma exacerbations and improves lung function in allergic (IgE-mediated) asthma
Reduces oral corticosteroid (OCS) requirements
Treatment response is not tied to standard pre-treatment biomarkers but influenced by genotype

JYB1904 Phase 1a

JYB1904 is an investigational anti-IgE agent in Phase 1a trials. It targets free IgE in a similar mechanism to Omalizumab and is being evaluated for allergic asthma with the aim of reducing free IgE levels.

Mepolizumab FDA Approved

Mepolizumab directly neutralizes IL-5, preventing eosinophil maturation and recruitment. It is approved for severe eosinophilic asthma (blood eosinophils ≥150 cells/μL at initiation).

Significantly reduces severe exacerbation rates and oral corticosteroid use
Reduces airway tissue remodeling markers (sub-basement membrane thickness, smooth muscle area)

Reslizumab FDA Approved

Reslizumab is an anti-IL-5 monoclonal antibody approved for severe eosinophilic asthma. It reduces exacerbation rates and OCS use. Administered intravenously (vs subcutaneous for Mepolizumab).

Benralizumab FDA Approved

Benralizumab targets the IL-5 receptor (IL-5Rα), depleting eosinophils via ADCC. Particularly effective in late-onset severe asthma. Subcutaneous dosing every 8 weeks after loading.

Reduces exacerbations, OCS, and improves airflow and lung hyperinflation
Reduces specialist visits and unscheduled primary care; mild adverse effect profile

Dupilumab FDA Approved

Dupilumab blocks the IL-4 receptor alpha subunit (IL-4Rα), simultaneously inhibiting both IL-4 and IL-13 signaling. This dual blockade addresses multiple downstream features of Type 2 asthma.

Improves FEV1 and reduces blood eosinophils, FeNO, and mucus hypersecretion
Reduces OCS requirements; approved for moderate-to-severe eosinophilic or OCS-dependent asthma
Minimal adverse effects (mainly URTI, bronchitis); well-tolerated in long-term use

Tezepelumab FDA Approved

Tezepelumab is a human IgG2 monoclonal antibody targeting TSLP (thymic stromal lymphopoietin), an epithelial-derived cytokine that acts upstream of multiple inflammatory pathways in both Th2-high and Th2-low asthma. This upstream mechanism gives it the broadest patient applicability of all current biologics.

Reduces exacerbations across all asthma phenotypes (including non-eosinophilic asthma — unique among biologics)
Demonstrates consistent exacerbation reductions across a wide range of baseline biomarker levels, including patients with low blood eosinophil counts — unique among biologics

Approved Biologics at a Glance

Drug	Target	Approval Status	Key Clinical Outcomes
Omalizumab	IgE	FDA approved	Reduces exacerbations, improves lung function in allergic asthma; response not tied to standard biomarkers
Mepolizumab	IL-5	FDA approved	Reduces exacerbations and OCS use in severe eosinophilic asthma; reduces airway remodeling
Reslizumab	IL-5	FDA approved	Reduces exacerbation rate and OCS use in severe eosinophilic asthma
Benralizumab	IL-5R	FDA approved	Reduces exacerbations, OCS; improves airflow; effective in late-onset severe asthma
Dupilumab	IL-4Rα (IL-4/IL-13)	FDA approved	Improves lung function, reduces eosinophils, OCS, and mucus; broad Type 2 asthma coverage
Tezepelumab	TSLP	FDA approved	Upstream epithelial alarmin blockade; works across all asthma phenotypes; reduces exacerbations broadly

Regenerative & Gene-Based Therapies

Clinical Readiness Note: These approaches are largely preclinical. They offer important mechanistic insights into asthma pathobiology but are not yet ready for clinical deployment. Most evidence comes from animal models or early-phase studies.

Mesenchymal Stem Cell (MSC) Therapy

Preclinical

MSCs are the most studied regenerative cell type in asthma. Their immunomodulatory properties can influence airway remodeling and persistent inflammation. Preclinical studies show reduced airway hyper-responsiveness and cytokine levels, and direct anti-inflammatory effects.

Challenge: Poorly defined MSC sources, inconsistent dosing, limited long-term safety data, and complex manufacturing for clinical-scale production.

siRNA / miRNA Gene Therapy

Preclinical

Short interfering RNA (siRNA) can silence specific mRNAs (e.g., IL-13, GATA3, STAT6) driving Th2 inflammation. MicroRNAs (miRNAs) modulate post-transcriptional gene expression across multiple targets simultaneously. Both approaches aim at molecular-level disease modification beyond what antibody therapy achieves.

Challenge: Delivery to airways without off-target effects; instability of RNA molecules; effective nanoparticle carriers needed for pulmonary delivery.

Tolerogenic mRNA Vaccines

Early Phase

Tolerogenic immunotherapy aims to re-establish immune tolerance to asthma-relevant allergens rather than broadly suppressing inflammation. Leveraging mRNA vaccine technology (proven in COVID-19), researchers are developing vaccines that encode allergen antigens to induce regulatory T cells and antigen-specific tolerance.

Challenge: Identifying the right antigens, preventing adverse immune reactions, and demonstrating long-term tolerance induction in human trials.

Nanoparticle Drug Delivery Systems

Conventional inhalers often deliver suboptimal drug doses to the lungs. Nanoparticle-based carriers offer targeted pulmonary deposition, controlled release, and improved drug stability — particularly relevant for biologics and RNA-based drugs that degrade rapidly in the airways.

PLGA Nanoparticles

Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are among the most studied pulmonary carriers. Biodegradable, biocompatible, and with tunable release kinetics. Preclinical evidence demonstrates successful delivery of corticosteroids (budesonide), small molecules, and biologics with extended release profiles.

Evidence level: Predominantly experimental. Clinical translation requires aerodynamic optimization, scale-up manufacturing, and long-term safety data.

Chitosan Nanoparticles

Chitosan is a natural polysaccharide with mucoadhesive properties that enhance drug residence time in the airways. Chitosan nanoparticles improve solubility and sustained release of drugs including salbutamol and corticosteroids in preclinical asthma models.

Evidence level: Preclinical. Mucoadhesion varies by formulation; in vivo efficacy and safety in humans not yet established.

Solid Lipid Nanoparticles (SLN)

Solid lipid nanoparticles use lipid-based matrices to improve stability and aerodynamic performance of inhaled drugs, especially hydrophobic compounds. In asthma models, SLNs demonstrate enhanced drug encapsulation efficiency and reduced enzymatic degradation in the airway mucus.

Evidence level: Experimental. Challenges include particle aggregation, reproducible nebulization, and regulatory path for inhaled lipid nanoparticles.

Smart Inhalers & Digital Health

Many patients with asthma have suboptimal inhaler technique, and adherence to controller therapy is chronically poor. Digital health tools address these behavioral and environmental barriers that pharmacological advances alone cannot resolve.

📱

Smart Inhalers

Connected sensor-equipped inhalers (e.g., Propeller Health, Hailie, Coughy) track dose timing, inhaler technique, and usage patterns. Real-time feedback to patients and clinicians improves adherence and identifies technique errors before they become exacerbation drivers.

Barriers: High device cost, battery/connectivity limitations, and integration with electronic health records remain unresolved in most healthcare systems.

💊

Digital Therapeutics (DTx)

App-based digital therapeutics provide guided asthma self-management — symptom tracking, medication reminders, personalized action plans, and cognitive-behavioral interventions for anxiety and depression comorbid with asthma. RCT evidence shows improvements in asthma control scores and quality of life.

Barriers: Digital health literacy gaps, regulatory variability across countries, and limited long-term effectiveness data beyond 12 months.

🌡️

Environmental Monitors

Wearable and home sensors monitor asthma-relevant environmental triggers: air pollutants (PM2.5, NO2), pollen counts, humidity, and mold levels. Integration with smart asthma action plans enables proactive trigger avoidance. Combined lung function + environmental sensing systems show feasibility for early intervention support.

Barriers: Sensor accuracy variation, complex data interpretation for patients without clinical guidance, and cost of multi-sensor home deployments.

Discussion & Future Perspectives

Recent advances reflect a broad shift toward precision medicine — biologics have demonstrated that mechanism-based targeting can significantly improve outcomes in severe Th2-high asthma. Yet this progress highlights persistent gaps: patients with non-Type 2 or mixed inflammatory disease remain underserved, and the majority of clinically relevant asthma subtypes still lack targeted therapy options.

Beyond biological efficacy, implementation challenges are a major barrier. High acquisition costs for biologics and experimental regenerative therapies limit access, especially in low-resource settings. Most evidence comes from short- to medium-term studies, leaving long-term effectiveness and safety largely uncharacterized.

Future development will likely focus on combination biologic therapy for mixed-phenotype asthma, biomarker-guided precision dosing, and AI-integrated digital health platforms that combine adherence monitoring with predictive exacerbation risk scoring. Gene-based and regenerative approaches will require robust clinical trial programmes with clearly defined endpoints.

Key Conclusions

Biologics targeting IgE, IL-5/IL-5R, IL-4/IL-13, and TSLP substantially reduce exacerbations and corticosteroid use in severe Type 2 asthma — these are now clinically established first-line options for severe disease.
Regenerative (MSC) and gene-based therapies (siRNA, miRNA, mRNA vaccines) offer mechanistically promising disease-modification but remain largely preclinical with limited clinical readiness.
Nanoparticle delivery systems (PLGA, chitosan, SLN) show potential to enhance pulmonary targeting and controlled release, but evidence is predominantly experimental.
Smart inhalers, digital therapeutics, and environmental monitors address behavioral and environmental barriers to asthma control, but real-world impact is constrained by cost, workflow integration, and limited long-term data.

Future Directions

Future asthma therapeutics are likely to focus on strategies extending beyond symptom control toward long-term disease modification: combination biologic therapy for mixed-endotype disease, AI-driven treatment selection from multi-omic biomarkers, biodegradable nanoparticle platforms for RNA therapeutics, and fully integrated digital health ecosystems that connect environmental sensing, medication adherence, and predictive analytics.

References (click to expand)

Selected key references from the paper (full reference list available in the original article on PMC).

Lim YX, Choo YN, Looi YT, et al. Emerging Therapeutic Strategies in Asthma. Curr Allergy Asthma Rep. 2026;26:17. doi:10.1007/s11882-026-01265-6
Global Asthma Network. The Global Asthma Report 2022. Auckland, New Zealand: Global Asthma Network; 2022.
Fahy JV. Type 2 inflammation in asthma — present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65.
Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–725.
Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157–171.

Emerging Therapeutic Strategies in Asthma